Corvus Pharmaceu Financials
This page shows Corvus Pharmaceu (CRVS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Corvus is functioning as a cash-burning R&D enterprise, with equity financing repeatedly used to rebuild liquidity rather than fund expansion.
FY2025's narrower net loss to-$15.3M looks better on the surface, but operating loss widened to-$43.0M . With operating cash outflow also deeper than the prior year at-$32.8M , the accounting result improved while the underlying cash cost of running the business worsened, implying help from items outside the core expense base rather than a genuine move toward self-funding.
Financing cash inflow of
The burn is operating, not capital-intensive: capital spending was only
Financial Health Signals
Corvus Pharmaceu does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Corvus Pharmaceu passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Corvus Pharmaceu reported a net loss of $15.3M while operations used $32.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Corvus Pharmaceu's EBITDA was -$42.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 56.1% from the prior year.
Corvus Pharmaceu reported -$15.3M in net income in fiscal year 2025. This represents an increase of 75.4% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Corvus Pharmaceu recorded an outflow of $33.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.
Corvus Pharmaceu held $4.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Corvus Pharmaceu's ROE was -25.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 166.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Corvus Pharmaceu invested $33.7M in research and development in fiscal year 2025. This represents an increase of 73.9% from the prior year.
Corvus Pharmaceu invested $174K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
CRVS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $33.7M+73.9% | $19.4M+17.3% | $16.5M-32.5% | $24.5M-16.0% | $29.1M-8.5% | $31.8M-16.2% | $38.0M-1.6% | $38.6M-16.7% | $46.3M+57.7% | $29.4M+158.6% | $11.4M+29773.7% | $38K |
| SG&A Expenses | N/A | $9.3M+13.3% | $8.2M+18.6% | $6.9M-15.0% | $8.1M-14.9% | $9.5M-20.2% | $11.9M+9.7% | $10.9M+2.3% | $10.6M+4.1% | $10.2M+34.1% | $7.6M+215.1% | $2.4M+1865.9% | $123K |
| Operating Income | N/A | -$43.0M-56.0% | -$27.5M-17.7% | -$23.4M+28.1% | -$32.6M+15.7% | -$38.6M+11.7% | -$43.8M+10.4% | -$48.9M+0.7% | -$49.2M+12.9% | -$56.5M-52.9% | -$37.0M-168.5% | -$13.8M-8452.8% | -$161K |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | N/A | -$15.3M+75.4% | -$62.3M-130.7% | -$27.0M+34.6% | -$41.3M+4.5% | -$43.2M-621.3% | -$6.0M+87.2% | -$46.7M+0.6% | -$46.9M+15.7% | -$55.7M-53.0% | -$36.4M-16.1% | -$31.3M-19362.7% | -$161K |
| EPS (Diluted) | — | -$0.53 | -$1.02-82.1% | -$0.56+37.1% | -$0.89+13.6% | -$1.03-415.0% | -$0.20+87.4% | -$1.59 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CRVS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $71.1M+3.2% | $68.9M+51.3% | $45.6M-33.2% | $68.2M-37.7% | $109.5M+28.0% | $85.5M+2.3% | $83.6M-29.3% | $118.2M+24.8% | $94.8M-32.4% | $140.2M+42.3% | $98.5M | N/A |
| Current Assets | $58.2M+7.0% | $54.4M+94.6% | $28.0M-36.0% | $43.7M-38.8% | $71.3M+57.3% | $45.3M-42.9% | $79.3M-31.4% | $115.6M+26.7% | $91.2M-32.9% | $136.0M+42.2% | $95.7M | N/A |
| Cash & Equivalents | $4.6M-47.6% | $8.7M-30.7% | $12.6M-4.1% | $13.2M-79.3% | $63.5M+285.6% | $16.5M+219.3% | $5.2M-86.9% | $39.2M-13.1% | $45.1M+793.2% | $5.0M+23.0% | $4.1M-67.2% | $12.5M |
| Accounts Receivable | $37K-50.7% | $75K+188.5% | $26K-95.6% | $588K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $9.9M-72.7% | $36.3M+429.0% | $6.9M-43.3% | $12.1M-1.4% | $12.3M-8.1% | $13.4M+6.7% | $12.5M+58.8% | $7.9M-20.6% | $9.9M+35.3% | $7.3M-94.3% | $129.6M | N/A |
| Current Liabilities | $9.4M-73.5% | $35.4M+415.4% | $6.9M-36.1% | $10.8M+10.9% | $9.7M-20.2% | $12.1M+18.8% | $10.2M+45.5% | $7.0M-21.7% | $9.0M+50.9% | $5.9M+93.6% | $3.1M | N/A |
| Total Equity | $61.2M+87.9% | $32.6M-15.8% | $38.7M-31.1% | $56.1M-42.2% | $97.2M+34.7% | $72.1M+1.5% | $71.1M-35.6% | $110.3M+30.1% | $84.8M-36.1% | $132.8M+527.0% | -$31.1M-19460.4% | -$159K |
| Retained Earnings | -$412.3M-3.8% | -$397.0M-18.6% | -$334.7M-8.8% | -$307.7M-15.5% | -$266.4M-19.4% | -$223.1M-2.8% | -$217.1M-27.4% | -$170.5M-38.0% | -$123.5M-82.0% | -$67.9M-115.5% | -$31.5M | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
CRVS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$44.5M | -$32.8M-29.0% | -$25.4M-6.2% | -$23.9M+11.4% | -$27.0M+26.4% | -$36.7M-5.6% | -$34.8M+6.8% | -$37.3M+8.9% | -$41.0M+11.3% | -$46.2M-65.9% | -$27.9M-145.9% | -$11.3M-11700.0% | -$96K |
| Capital Expenditures | $698K | $174K | N/A | $34K-87.4% | $269K+5280.0% | $5K-93.4% | $76K+204.0% | $25K-93.0% | $355K+33.5% | $266K-87.9% | $2.2M+25.9% | $1.7M | N/A |
| Free Cash Flow | -$45.2M | -$33.0M | N/A | -$24.0M+12.2% | -$27.3M+25.7% | -$36.7M-5.4% | -$34.9M+6.7% | -$37.3M+9.7% | -$41.3M+11.0% | -$46.5M-54.6% | -$30.1M-129.9% | -$13.1M | N/A |
| Investing Cash Flow | -$142.5M | -$7.8M+71.6% | -$27.5M-276.8% | $15.5M+166.8% | -$23.3M-208.0% | $21.6M-51.8% | $44.8M+1275.4% | $3.3M+110.8% | -$30.2M-135.6% | $84.8M+299.3% | -$42.6M+53.8% | -$92.0M | N/A |
| Financing Cash Flow | $191.3M | $36.4M-25.7% | $49.0M+524.2% | $7.9M | $0-100.0% | $62.2M+4644.9% | $1.3M+5358.3% | $24K-100.0% | $65.3M+4426.4% | $1.4M-98.0% | $71.4M-24.8% | $94.9M | N/A |
| Dividends Paid | N/A | $0 | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CRVS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | -25.0%+166.3pp | -191.3%-121.5pp | -69.8%+3.8pp | -73.6%-29.1pp | -44.5%-36.2pp | -8.3%+57.3pp | -65.6%-23.1pp | -42.5%+23.1pp | -65.6%-38.2pp | -27.4% | N/A | N/A |
| Return on Assets | -21.5%+68.9pp | -90.4%-31.1pp | -59.3%+1.3pp | -60.5%-21.0pp | -39.5%-32.5pp | -7.0%+48.8pp | -55.8%-16.1pp | -39.7%+19.0pp | -58.7%-32.8pp | -25.9%+5.9pp | -31.8% | N/A |
| Current Ratio | 6.21+4.7x | 1.54-2.5x | 4.070.0x | 4.06-3.3x | 7.36+3.6x | 3.73-4.0x | 7.76-8.7x | 16.45+6.3x | 10.17-12.7x | 22.89-8.3x | 31.16 | N/A |
| Debt-to-Equity | 0.16-1.0x | 1.12+0.9x | 0.180.0x | 0.22+0.1x | 0.13-0.1x | 0.190.0x | 0.18+0.1x | 0.070.0x | 0.12+0.1x | 0.06 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Corvus Pharmaceu Ranks
Frequently Asked Questions
Is Corvus Pharmaceu profitable?
No, Corvus Pharmaceu (CRVS) reported a net income of -$15.3M in fiscal year 2025.
What is Corvus Pharmaceu's EBITDA?
Corvus Pharmaceu (CRVS) had EBITDA of -$42.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Corvus Pharmaceu's return on equity (ROE)?
Corvus Pharmaceu (CRVS) has a return on equity of -25.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Corvus Pharmaceu's free cash flow?
Corvus Pharmaceu (CRVS) recorded an outflow of $33.0M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Corvus Pharmaceu's operating cash flow?
Corvus Pharmaceu (CRVS) recorded an outflow of $32.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Corvus Pharmaceu's total assets?
Corvus Pharmaceu (CRVS) had $71.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Corvus Pharmaceu's capital expenditures?
Corvus Pharmaceu (CRVS) invested $174K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Corvus Pharmaceu spend on research and development?
Corvus Pharmaceu (CRVS) invested $33.7M in research and development during fiscal year 2025.
What is Corvus Pharmaceu's current ratio?
Corvus Pharmaceu (CRVS) had a current ratio of 6.21 as of fiscal year 2025, which is generally considered healthy.
What is Corvus Pharmaceu's debt-to-equity ratio?
Corvus Pharmaceu (CRVS) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Corvus Pharmaceu's return on assets (ROA)?
Corvus Pharmaceu (CRVS) had a return on assets of -21.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Corvus Pharmaceu's cash runway?
Based on fiscal year 2025 data, Corvus Pharmaceu (CRVS) had $4.6M in cash against an annual operating cash burn of $32.8M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Corvus Pharmaceu's Piotroski F-Score?
Corvus Pharmaceu (CRVS) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Corvus Pharmaceu's earnings high quality?
Corvus Pharmaceu (CRVS) reported a net loss of $15.3M while operations used $32.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.